Biophytis (BPTSY) Competitors $2.00 +0.20 (+10.80%) As of 08/15/2025 02:08 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock BPTSY vs. UPC, CANF, GLMD, ADXS, ADTX, PBM, AIM, SXTP, AKAN, and WINTShould you be buying Biophytis stock or one of its competitors? The main competitors of Biophytis include Universe Pharmaceuticals (UPC), Can-Fite BioPharma (CANF), Galmed Pharmaceuticals (GLMD), Ayala Pharmaceuticals (ADXS), Aditxt (ADTX), Psyence Biomedical (PBM), AIM ImmunoTech (AIM), 60 Degrees Pharmaceuticals (SXTP), Akanda (AKAN), and Windtree Therapeutics (WINT). These companies are all part of the "pharmaceutical products" industry. Biophytis vs. Its Competitors Universe Pharmaceuticals Can-Fite BioPharma Galmed Pharmaceuticals Ayala Pharmaceuticals Aditxt Psyence Biomedical AIM ImmunoTech 60 Degrees Pharmaceuticals Akanda Windtree Therapeutics Universe Pharmaceuticals (NYSE:UPC) and Biophytis (NASDAQ:BPTSY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends. Does the media favor UPC or BPTSY? In the previous week, Biophytis had 1 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 1 mentions for Biophytis and 0 mentions for Universe Pharmaceuticals. Biophytis' average media sentiment score of 1.00 beat Universe Pharmaceuticals' score of 0.00 indicating that Biophytis is being referred to more favorably in the news media. Company Overall Sentiment Universe Pharmaceuticals Neutral Biophytis Positive Do institutionals & insiders believe in UPC or BPTSY? 0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by insiders. Comparatively, 3.7% of Biophytis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, UPC or BPTSY? Universe Pharmaceuticals has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500. Comparatively, Biophytis has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Is UPC or BPTSY more profitable? Company Net Margins Return on Equity Return on Assets Universe PharmaceuticalsN/A N/A N/A Biophytis N/A N/A N/A Which has stronger valuation & earnings, UPC or BPTSY? Universe Pharmaceuticals has higher revenue and earnings than Biophytis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUniverse Pharmaceuticals$19.29M0.10-$6.16MN/AN/ABiophytisN/AN/A-$18.43MN/AN/A SummaryUniverse Pharmaceuticals beats Biophytis on 5 of the 7 factors compared between the two stocks. Get Biophytis News Delivered to You Automatically Sign up to receive the latest news and ratings for BPTSY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BPTSY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPTSY vs. The Competition Export to ExcelMetricBiophytisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$702K$822.97M$5.70B$9.79BDividend YieldN/A4.84%3.77%4.10%P/E RatioN/A1.1830.8625.25Price / SalesN/A25.66403.9088.50Price / CashN/A19.5625.2228.45Price / Book-0.126.599.516.00Net Income-$18.43M-$4.67M$3.26B$265.34M7 Day PerformanceN/A0.55%4.49%2.81%1 Month Performance10.80%0.13%5.18%1.50%1 Year PerformanceN/A15.33%31.98%25.46% Biophytis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPTSYBiophytisN/A$2.00+10.8%N/AN/A$702KN/A0.0030Positive NewsShort Interest ↓Gap UpUPCUniverse PharmaceuticalsN/A$4.40+29.0%N/A-99.8%$2.48M$19.29M0.00220CANFCan-Fite BioPharma1.9589 of 5 stars$0.69+4.3%$14.00+1,934.0%-73.9%$2.44M$674K-0.388Short Interest ↑GLMDGalmed Pharmaceuticals1.9824 of 5 stars$1.46+2.8%N/A-57.1%$2.35MN/A-0.0920Short Interest ↓Gap UpADXSAyala PharmaceuticalsN/A$0.05+2.4%N/A+168.0%$2.23M$3.24M-0.0120Gap UpADTXAditxtN/A$1.05+1.9%N/A-100.0%$2.18M$130K0.0060Positive NewsEarnings ReportPBMPsyence Biomedical2.272 of 5 stars$3.22-12.5%N/A-99.0%$2.09MN/A0.00N/APositive NewsShort Interest ↓Gap DownAIMAIM ImmunoTech1.3688 of 5 stars$2.67+1.5%$275.00+10,199.6%-91.3%$2.04M$146K-5.6820Gap UpSXTP60 Degrees Pharmaceuticals2.6716 of 5 stars$1.35flat$7.00+418.5%-83.1%$1.99M$300K-0.033Earnings ReportShort Interest ↓AKANAkanda1.1264 of 5 stars$1.37+3.0%N/A-50.4%$1.90M$840K0.00110Positive NewsShort Interest ↑WINTWindtree Therapeutics2.4926 of 5 stars$0.54+3.4%$350.00+65,222.9%-99.9%$1.90MN/A0.0030Short Interest ↓ Related Companies and Tools Related Companies Universe Pharmaceuticals Alternatives Can-Fite BioPharma Alternatives Galmed Pharmaceuticals Alternatives Ayala Pharmaceuticals Alternatives Aditxt Alternatives Psyence Biomedical Alternatives AIM ImmunoTech Alternatives 60 Degrees Pharmaceuticals Alternatives Akanda Alternatives Windtree Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BPTSY) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biophytis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biophytis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access